Paul Schneider
Director of Finance/CFO bij FREELINE THERAPEUTICS HOLDINGS PLC
Profiel
Paul M.
Schneider is currently the Chief Financial Officer at Freeline Therapeutics Holdings Plc.
Prior to his current position, he served as the Senior Vice President-Finance at Casebia Therapeutics LLC from 2016 to 2019.
He also held the position of Senior Vice President-Finance & Operations at Exo Therapeutics, Inc. Mr. Schneider completed his undergraduate degree at Boston College.
Actieve functies van Paul Schneider
| Bedrijven | Functie | Begin |
|---|---|---|
| FREELINE THERAPEUTICS HOLDINGS PLC | Director of Finance/CFO | 16-05-2022 |
Eerdere bekende functies van Paul Schneider
| Bedrijven | Functie | Einde |
|---|---|---|
Casebia Therapeutics LLC
 Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Casebia Therapeutics LLC is a joint venture company that focuses on discovering, developing, and commercializing gene-editing therapeutics to treat genetic causes of bleeding disorders and autoimmune diseases. The company is based in Cambridge, MA. | Corporate Officer/Principal | 01-09-2019 |
Exo Therapeutics, Inc.
 Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA. | Director of Finance/CFO | - |
Opleiding van Paul Schneider
| Boston College | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
Casebia Therapeutics LLC
Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Casebia Therapeutics LLC is a joint venture company that focuses on discovering, developing, and commercializing gene-editing therapeutics to treat genetic causes of bleeding disorders and autoimmune diseases. The company is based in Cambridge, MA. | Health Technology |
Exo Therapeutics, Inc.
Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA. | Health Technology |
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
